BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc., a clinical stage biotechnology company, today announced that the first patients have been enrolled in a Phase 1 clinical trial to evaluate its novel immunotherapy ADU-623 in patients with high-grade glioma, a form of brain cancer. The trial is being conducted by leading investigators at the Earle A. Chiles Research Institute at Providence Cancer Center in Portland, Oregon. The project has been funded by grants from the Kuni Foundation and Providence Portland Medical Foundation.
ADU-623, based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immunotherapy platform, has been engineered to promote a potent innate immune response as well as an adaptive immune response to two cancer-specific antigens, EGFRvIII and NY-ESO-1.
The Phase 1 clinical trial will enroll up to 38 patients with high-grade glioma who have previously been treated with standard of care therapy. The study will evaluate three dose levels of ADU-623 with the primary goal of establishing the safety of the immunotherapy and to determine the optimal dose. The trial will also evaluate the patients’ tumor responses and immune response to the ADU-623 immunotherapy.
“Providence is a state-of-the-art cancer treatment center and we are pleased to collaborate with them on the development of ADU-623 in this important indication,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “The study builds on our recent clinical advances with the LADD immunotherapy platform in pancreatic cancer and mesothelioma.”
“For more than 30 years, our field has made little progress in extending the survival of patients with glioblastoma,” said Dr. Gore, co-medical director, cranial services, Providence Brain and Spine Institute. “I firmly believe that immunotherapy is the new horizon in the treatment of this disorder. This trial has the potential to have a significant impact on the standard course of this disease.”
About LADD and ADU-623
LADD is Aduro’s proprietary platform of live-attenuated double-deleted Listeria monocytogenes strains that have been engineered to induce a potent innate immune response and to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. ADU-623 is engineered to express EGFRvIII and NY-ESO-1, which are expressed in glioblastoma and other cancers.
About Aduro BioTech, Inc.
Aduro BioTech, Inc. is a private, clinical-stage biotechnology company focused on immunotherapy for cancer. Aduro has ongoing clinical trials with its LADD platform in pancreatic cancer, mesothelioma and glioblastoma and development programs in non-small cell lung cancer, ovarian cancer and prostate cancer. The company is also developing clinical candidates using novel small molecules that activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit www.adurobiotech.com.